Regina Salvat adds a business development perspective to the team which is central to our discussions with pharma companies in understanding potential assets ready to be spun out and building relationships with our current company exits. She focuses on therapeutics investments and has been essential to our investment team. Regina is currently a board observer for Alkeus, Atsena, BioAge, and OnCusp.
Before joining Sofinnova in 2020, Regina held the position of Associate Director of Strategy and Corporate Development at Rubius Therapeutics. Prior to her tenure at Rubius, she provided strategic consulting support to a diverse range of bio-pharmaceutical companies at Huron Consulting Group, which is now part of Oliver Wyman. Regina’s extensive industry experience also includes a role as a Senior Associate Scientist in Cell Line Development within Bioprocess R&D at Pfizer, adding a valuable bioprocess dimension to her versatile skill set.
Regina is a distinguished alumna of the Thayer School of Engineering at Dartmouth College, where she was honored as a Clare Boothe Luce Fellow and Innovation Fellow. During her graduate studies at Dartmouth, Regina’s research in Protein Engineering paved the way for commercialization in the form of Stealth Biologics, which was later acquired by Insmed. Her academic journey also includes a B.S. in Biological Engineering and an M.Eng. in Biomedical Engineering, both earned at Cornell University.
